Biomarin Pharmaceutical (BMRN) EBT Margin (2009 - 2026)

Biomarin Pharmaceutical has disclosed EBT Margin across 18 years of filings, most recently posting 18.43% for Q1 2026.

• Quarterly EBT Margin fell 1352.0% year-over-year to 18.43% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.89% (down 1096.0% YoY) and the FY2025 annual result came in at 14.98%, down 401.0% from the prior year.
• EBT Margin advanced to 18.43% in Q1 2026, from 3.1% in the prior quarter.
• Over five years, EBT Margin peaked at 36.09% in Q2 2025 and troughed at 3.39% in Q3 2025.
• A 5-year average of 12.7% and a median of 11.9% in 2023 frame the typical range for EBT Margin.
• Annual changes were most pronounced in 2022 — EBT Margin soared 2106 bps — and 2025, when it sank 2580 bps.
• Tracing BMRN's EBT Margin over 5 years: stood at 3.27% in 2022, then jumped by 192 bps to 2.99% in 2023, then jumped by 659 bps to 22.7% in 2024, then plunged by 114 bps to 3.1% in 2025, then jumped by 694 bps to 18.43% in 2026.
• Business Quant data shows BMRN's EBT Margin at 18.43% in Q1 2026, 3.1% in Q4 2025, and 3.39% in Q3 2025.